| 0 (0%) | 01-19 18:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.02 |
1-year : | 1.2 |
| Resists | First : | 0.87 |
Second : | 1.02 |
| Pivot price | 0.62 |
|||
| Supports | First : | 0.52 |
Second : | 0.3 |
| MAs | MA(5) : | 0.68 |
MA(20) : | 0.59 |
| MA(100) : | 0.66 |
MA(250) : | 0.95 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.7 |
D(3) : | 72.4 |
| RSI | RSI(14): 54.1 |
|||
| 52-week | High : | 4.73 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VCNX ] has closed below upper band by 32.4%. Bollinger Bands are 8.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.69 - 0.69 | 0.69 - 0.69 |
| Low: | 0.3 - 0.3 | 0.3 - 0.3 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Mon, 19 Jan 2026
Vaccinex (VCNX) Stock: Micro-Cap Volatility Meets Biotech Ambition After A Steep Slide - AD HOC NEWS
Mon, 19 Jan 2026
Vaccinex Inc (VCNX) Is Going Wild: Tiny Biotech, Massive Risk – Is It Worth the Hype? - AD HOC NEWS
Tue, 23 Dec 2025
New Alzheimer’s antibody trial gets $60M boost in search for treatment - Stock Titan
Mon, 10 Mar 2025
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
Fri, 07 Mar 2025
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.18e+006 (%) |
| Held by Institutions | 11.5 (%) |
| Shares Short | 128 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.864e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 590.1 % |
| Return on Equity (ttm) | -376.1 % |
| Qtrly Rev. Growth | 601000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.47407e+007 |
| Qtrly Earnings Growth | -8.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 62110 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|